{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Biological+Availability",
    "query": {
      "condition": "Biological Availability"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1083,
    "total_pages": 109,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Biological+Availability&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T03:21:56.004Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06533280",
      "title": "VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Part A, C and D: VH3739937 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Part A: VH3739937 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Part A and C: Placebo",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment A",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment B",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment C",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment D",
          "type": "DRUG"
        },
        {
          "name": "Part B: Treatment E",
          "type": "DRUG"
        },
        {
          "name": "Part D: Probe cocktail",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 0,
      "start_date": "2024-08-02",
      "completion_date": "2024-08-14",
      "has_results": false,
      "last_update_posted_date": "2025-04-22",
      "last_synced_at": "2026-07-23T03:21:56.004Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06533280"
    },
    {
      "nct_id": "NCT02475161",
      "title": "A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "JNJ-42847922",
          "type": "DRUG"
        },
        {
          "name": "Rabeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 16,
      "start_date": "2015-06",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-07-23T03:21:56.004Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02475161"
    },
    {
      "nct_id": "NCT06198686",
      "title": "An Evaluation of The Absolute Bioavailability of TH104",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Nalmefene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tharimmune Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2024-01-26",
      "completion_date": "2024-11-06",
      "has_results": false,
      "last_update_posted_date": "2025-04-08",
      "last_synced_at": "2026-07-23T03:21:56.004Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06198686"
    },
    {
      "nct_id": "NCT05918822",
      "title": "A Study of Maribavir Pediatric Formulation in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Maribavir Commercial Tablet Formulation",
          "type": "DRUG"
        },
        {
          "name": "Maribavir Pediatric Powder-for-oral Suspension Formulation",
          "type": "DRUG"
        },
        {
          "name": "Rabeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2023-07-25",
      "completion_date": "2023-09-01",
      "has_results": true,
      "last_update_posted_date": "2024-09-26",
      "last_synced_at": "2026-07-23T03:21:56.004Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05918822"
    },
    {
      "nct_id": "NCT02641353",
      "title": "Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and to Assess Effect of Food on the Pharmacokinetics (PK) of the Oral Suspension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Apremilast Tablet",
          "type": "DRUG"
        },
        {
          "name": "Apremilast Oral Suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 34,
      "start_date": "2016-01-05",
      "completion_date": "2016-02-27",
      "has_results": true,
      "last_update_posted_date": "2021-08-05",
      "last_synced_at": "2026-07-23T03:21:56.004Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02641353"
    },
    {
      "nct_id": "NCT06649877",
      "title": "MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "MK-6194",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 16,
      "start_date": "2023-03-20",
      "completion_date": "2023-07-13",
      "has_results": false,
      "last_update_posted_date": "2024-10-21",
      "last_synced_at": "2026-07-23T03:21:56.004Z",
      "location_count": 1,
      "location_summary": "South Miami, Florida",
      "locations": [
        {
          "city": "South Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06649877"
    },
    {
      "nct_id": "NCT03311373",
      "title": "A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Regimen A",
          "type": "DRUG"
        },
        {
          "name": "Regimen B",
          "type": "DRUG"
        },
        {
          "name": "Regimen C",
          "type": "DRUG"
        },
        {
          "name": "Regimen D",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pearl Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 56,
      "start_date": "2017-10-17",
      "completion_date": "2017-12-15",
      "has_results": true,
      "last_update_posted_date": "2020-06-11",
      "last_synced_at": "2026-07-23T03:21:56.004Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03311373"
    },
    {
      "nct_id": "NCT04591782",
      "title": "Investigation of PJ vs. Sugar on Glucose Levels in Healthy and Prediabetic Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabete Type 2",
        "Pre Diabetes"
      ],
      "interventions": [
        {
          "name": "PomJuice",
          "type": "OTHER"
        },
        {
          "name": "Water",
          "type": "OTHER"
        },
        {
          "name": "Sugar Water",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "20 Years to 50 Years"
      },
      "enrollment_count": 42,
      "start_date": "2019-02-01",
      "completion_date": "2021-12-20",
      "has_results": false,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-07-23T03:21:56.004Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04591782"
    },
    {
      "nct_id": "NCT01172496",
      "title": "A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "treprostinil diethanolamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2010-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-10-13",
      "last_synced_at": "2026-07-23T03:21:56.004Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01172496"
    },
    {
      "nct_id": "NCT04600505",
      "title": "A Study to Assess Drug Absorption of Fixed Dose Combinations of Budesonide, Glycopyrronium, and Formoterol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Treatment A",
          "type": "DRUG"
        },
        {
          "name": "Treatment B",
          "type": "DRUG"
        },
        {
          "name": "Treatment C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "18 Years to 60 Years · Male only"
      },
      "enrollment_count": 47,
      "start_date": "2020-10-19",
      "completion_date": "2021-05-17",
      "has_results": true,
      "last_update_posted_date": "2023-01-23",
      "last_synced_at": "2026-07-23T03:21:56.004Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04600505"
    }
  ]
}